Innovent Biologics, Pfizer strike $10.5 billion cancer drug deal amid China biotech boom
The partnership covers 12 early-stage cancer medicines and includes a $650 million upfront payment plus milestone payments, Innovent said.
- On Thursday, May 28, 2026, Pfizer Inc. and Innovent Biologics, Inc. announced a strategic global licensing agreement to develop 12 early-stage cancer medicines valued at up to $10.5 billion.
- This collaboration leverages Innovent's proprietary discovery engine alongside Pfizer's global research capabilities, as drugmakers increasingly tap China's booming biotech pipeline to address demand for new oncology therapies.
- Innovent will receive a $650 million upfront payment and is eligible for up to $9.85 billion in milestone payments, while the companies will co-develop four programs with shared profits in the United States and Europe.
- Following the announcement, Innovent shares rose 6.41% to HK$79.65, though the transaction remains subject to required regulatory approvals before development can commence.
- Large pharmaceutical companies are utilizing licensing as a surgical tool to address near-term pipeline gaps ahead of the '2026 2030 patent cliff,' according to a report by Gibson Dunn.
16 Articles
16 Articles
Pfizer Strikes Up To $10.5 Billion Deal With Innovent Biologics - Pfizer (NYSE:PFE)
Pfizer Inc. (NYSE:PFE) and China’s Innovent Biologics have announced a global licensing and collaboration agreement. The deal, valued at up to $10.5 billion, is set to develop 12 early-stage cancer drugs. The agreement comprises an upfront payment of $650 million to Innovent, with potential development, regulatory, and commercial milestone payments reaching up to $9.85 billion. The collaboration encompasses a portfolio of antibody-drug conjugate…
China’s Innovent Biologics signs US$10.5b Pfizer deal for 12 cancer drug trials
China’s Innovent Biologics has signed a global collaboration with pharmaceutical giant Pfizer worth up to US$10.5 billion to jointly develop 12 cancer treatment programmes. The Hong Kong-listed drug maker said it would receive an upfront payment of US$650 million from Pfizer, and it is eligible for up to US$9.85 billion tied to development, regulatory and commercial milestone payments, according to an exchange filing on Friday. Innovent, which i…
Innovent Biologics, Pfizer strike $10.5 billion cancer drug deal amid China biotech boom
May 29 (Reuters) – China’s Innovent Biologics and U.S. pharma giant Pfizer have agreed to a global licensing and collaboration deal worth up to $10.5 billion to develop 12 early-stage cancer medicines, as global drugmakers race to tap China’s booming biotech pipeline. The deal also includes a $650 million upfront payment to Innovent and up to $9.85 billion in potential development, regulatory and commercial milestone payments. The deal comes a…
PR Newswire
The Times and DemocratInnovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines
/PRNewswire/ -- Innovent Biologics, Inc. (01801.HK) and Pfizer Inc. (NYSE: PFE), today announced the companies have entered into a strategic global licensing...
Coverage Details
Bias Distribution
- 87% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
